Testosterone in ageing men

Bibliography

• GRAY A, FELDMAN HA, MCKINLAY JB, LONGCOPE C: Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J. Clin. Endocrinol. Metab. (1991) 73 :1016–1025.
   PubMed Web of Science ®Google Scholar
• ••This study provided for the first time epidemiologicalevidence of variations of androgen hormones in normal and pathological subjects in contrast to previous studies in which only smaller, uncontrolled, or questionably represen-tative samples were analysed.
   Google Scholar
• BELANGER A, CANDAS B, DUPONT A et al.: Changes in serum concentrations of conjugated and unconju-gated steroids in 40- to 80-year-old men. J. Clin. Endocrinol. Metab. (1994) 79:1086–1090.
   PubMed Web of Science ®Google Scholar
• •The large number of patients recruited in this study (2000 male subjects aged 40–80 years) reinforced the conclusions of the authors in demonstrating the changes in the whole battery of conjugated and in non-conjugated steroids occurring with ageing.
   Google Scholar
• TSITOURAS PD, BULAT T: The aging male reproductive system. Endocrinol. Metab. Clin. North. Am. (1995) 24:297–315.
   PubMed Web of Science ®Google Scholar
• GAMBINERI A, PASQUALI R: Testosterone therapy in men: clinical and pharmacological perspectives. J Endocrinol. Invest. (2000) 23:196–214.
   PubMed Web of Science ®Google Scholar
• VERMEULEN A: Androgens in the aging male. J. Clin. Endocrinol. Metab. (1991) 73:221–224.
   PubMed Web of Science ®Google Scholar
• •This review proposes the aetiopathogenetic mechanisms supposed to take part in the decrease of the T levels observed in the ageing process.
   Google Scholar
• BREMNER WJ, VITIELLO MV, PRINZ PN: Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. (1983) 56:1278–1281.
   PubMed Web of Science ®Google Scholar
• VELDHUIS LD, URBAN RJ, LIZARRALDE G, JOHNSON ML, IRANMANESH A: Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging men. J. Clin. Endocrinol. Metab. (1992) 75:707–713.
   PubMed Web of Science ®Google Scholar
• WINTERS SJ, SHERINS RJ, TROEN P: The gonadotropic suppressive activity of androgens is increased in elderly men. Metabolism (1984) 33:1052–1059.
   PubMed Web of Science ®Google Scholar
• WINTERS SJ, ATKINSON L FOR THE TESTODERM STUDY GROUP: Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that aging enhances testosterone negative feedback. Clin. Endocrinol. (1997) 47:317–322.
   PubMed Web of Science ®Google Scholar
• VERMEULEN A, KAUFMAN JM, GIAGULLI VA: Influence of some biological indices on sex hormone binding globulin and androgen levels in aging and obese males. J. Clin. Endocrinol. Metab. (1996) 81:1821–1827.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, KAISER FE, SIH R, HADAR R, PERRY III HM: Testosterone and frailty. Clin. Geriatr. Med. (1997) 13 :685–695.
   PubMed Web of Science ®Google Scholar
• MORLEY JE: Testosterone replacement and the physiol-ogic aspects of aging in men. Mayo Clin. Proc. (2000) 75 (Suppl.):S83–S87.
   Google Scholar
• BHASIN S, BAGATELL CJ, BREMNER WJ et al.: Issues in testosterone replacement in older men. J. Clin. Endocrinol. Metab. (1998) 83:3435–3448.
   PubMed Web of Science ®Google Scholar
• ••This recent review brilliantly highlighted the mostinteresting and controversial questions related to androgen therapy.
   Google Scholar
• KAUFMAN JM, VERMEULEN A: Androgens in male senescence. In: Testosterone: Action, Deficiency, Substitu-tion. Nieschlag E, Behre HM (2nd Ed.), Springer, Germany (1998):437–471.
   Google Scholar
• TREMBLAY RR, MORALES A: Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. The Aging Male (1998) 1:213–218.
   Google Scholar
• NIESCHLAG E, BEHRE HM: Pharmacology and clinical uses of testosterone. In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM (2nd Ed.), Springer, Germany (1998):293–328.
   Google Scholar
• HORST HJ, HOLTJE WJ, DENNIS M, COERT A, GEELEN J, VOIGT KD: Lymphatic absorption and metabolism of orally administered testosterone undecanoate in men. Kiln. Wochenschr. (1976) 54:875–879.
   PubMedGoogle Scholar
• COERT A, GREELEN J, DE VISSER J, VAN DER VIES J: The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol. (1975) 79:789–800.
   PubMedGoogle Scholar
• NIESCHLAG E, MAUSS J, COERT A, KICOVIC P: Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol. (1975) 79:366.
   PubMedGoogle Scholar
• SCHORMEYER T, WICKINGS EJ, FREISCHEM CW, NIESCHLAG E: Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol. (1983) 102:456–462.
   PubMedGoogle Scholar
• HONRATH WL, WOLFF A, MELI A: The influence of the amount of solvent (sesame oil) on the degree and duration of action of subcutaneously administered testosterone anditspropioate. Steroids (1963) 2:425–428.
   Web of Science ®Google Scholar
• JAMES KC, NICHOLLS PJ, ROBERTS M: Biological half-lives of 4-14C testosterone and some of its esters after injection into the rat. J. Pharm. Pharmacol. (1969) 21:24–27.
   PubMed Web of Science ®Google Scholar
• BHASIN S, BREMNER WJ: Emerging issues in androgen replacement therapy. J. Clin. Endocrinol. Metab. (1997) 02:3–8.
   Google Scholar
• •This review has the merit of summarising the therapeutic systems of T delivery and providing indications concerning the monitoring of replacement therapy in hypogonadal men without age distinction.
   Google Scholar
• FUJIOKA M, SHINOHARA Y, BABA S, IRIE M, INOUE K: Pharmacokinetic properties of testosterone propionate in normal men. J. Clin. Endocrinol. Metab. (1986) 63:1361–1364.
   PubMed Web of Science ®Google Scholar
• VAN DER VIES J: Model studies in vitrowith long-acting hormonal preparations. Acta Endocrinol. (1970) 64:656–669.
   PubMedGoogle Scholar
• NIESCHLAG E, COPPERS HJ, WIEGELMANN W, WICKINGS EJ: Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm. Res. (1976) 7:138–145.
   PubMed Web of Science ®Google Scholar
• SCHULTE-BEERBOHL M, NIESCHLAG E: Comparison of testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone in serum after injection of testosterone enanthate or testos-terone cypionate. Fertil. Steril. (1980) 33:201–203.
   PubMed Web of Science ®Google Scholar
• NANKIN HR: Hormone kinetics after intramusculartestosterone cypionate. Fertil. Steril (1987) 47:1004–1009.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, LAWRENCE DA: Treatment of male hypogonadism with testosterone enanthate. j Clin. Endocrinol. Metab. (1980) 51:1335–1339.
   PubMed Web of Science ®Google Scholar
• SOKOL RZ, PALACIOS A, CAMPFIELD LA, SAUL C,SWERDLOFF RS: Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil. Steril. (1982) 37:425–430.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, NIESCHLAG E: Comparative pharmacoki- netics of testosterone esters. In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM (2nd Ed.), Springer, Germany (1998):329–348.
   Google Scholar
• ••This article appeared in a recent book in which it is hard forthe reader to rank the different contributions due to the constant high scientific profile of each chapter. This chapter represents a milestone for the understanding of the different pharmacokinetic profiles of each different T ester.
   Google Scholar
• ARVER S, MEIKLE AW, DOBS AS, SANDERS S, MAZER NA: Hypogonadal men treated with the Androderm testos-terone transdermal system had fewer abnormal hematocrit elevations than those treated with testos-terone enanthate injections. Endocrine Society 79th Annual Meeting (1997):P01–327.
   Google Scholar
• MEIKLE AW: A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM (2nd Ed.), Springer, Germany (1998):389–422.
   Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Pharma- cokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. (1990) 71:216–222.
   PubMed Web of Science ®Google Scholar
• •This study reports the first detailed pharmacokinetic and pharmacodynamic study of testosterone pellets in hypogonadal men largely contributing to the renovated interest in this delivery system.
   Google Scholar
• HANDELSMAN DJ: Clinical pharmacology of testos-terone pellet implants. In: Testosterone: Action Deficiency, Substitution. Nieschlag E, Behre HM (2nd Ed.), Springer, Germany (1998):349–364.
   Google Scholar
• FELDMAN RJ, MAIBACH HI: Regional variation in percutaneous penetration of 14C cortisol in man. J Invest. Dermatol. (1967) 48:181–183.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM GR, CORDERO E, THORNBY JI: Testos-terone replacement with transdermal therapeutic systems. JAMA (1989) 261:2525–2530.
   PubMed Web of Science ®Google Scholar
• FINDLAY JC, PLACE VA, SNYDER PJ: Transdermaldelivery of testosterone. J. Clin. Endocrinol. Metab. (1987) 64:266–268.
   PubMed Web of Science ®Google Scholar
• KORENMAN SG, VIOSCA S, GURALNIK DGM, PLACE V,CAMPBELL P, DAVIS SS: Androgen therapy of hypogonadal men with transscrotal testosterone systems. Am. J. Med. (1987) 83:471–478.
   PubMed Web of Science ®Google Scholar
• AHMED SR, BOUCHER AE, MANNI A, SANTEN RJ, BARTHOLOMEW M, DEMERS LM: Transdermal testos-terone therapy in the treatment of male hypogona-dism. j Clin. Endocrinol. Metab. (1988) 66:546–551.
   PubMed Web of Science ®Google Scholar
• FINDLAY JC, PLACE V, SNYDER PJ: Treatment of primaryhypogonadism in men by the transdermal administra-tion of testosterone. J. Clin. Endocrinol. Metab. (1989) 68:369–373.
   PubMed Web of Science ®Google Scholar
• WILSON JD, WALKER JD: The conversion of testos-terone to 5 a-androstane-1117-01-3 one (dihydro testosterone) by skin slices of men. J Clin. Invest. (1969) 48:371–379.
   PubMed Web of Science ®Google Scholar
• PLACE VA, ATKINSON L, PRATHER DA et al.: Transdermaltestosterone replacement through genital skin. In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM, Springer, Germany (1990):165–181.
   Google Scholar
• MEIKLE AW,ARVER S, DOBS AS, SANDERS SW, RAJARAML, MAZER NA: Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J. Clin. Endocrinol. Metab. (1996) 81:1832–1840.
   PubMed Web of Science ®Google Scholar
• •This interesting study is a section of a Phase III multicentre study in which a large population of hypogonadal men were recruited. The importance of this contribution is related to its detailed description of pharmacokinetics and properties of the permeation-enhanced testosterone transdermal system. The possibility of the potential influence of application site in the efficacy of the compound is highlighted.
   Google Scholar
• MEIKLE AW, MAZER NA, MOELLMER JF et al.: Enhancedtransdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Clin. Endocrinol. Metab. (1992) 74:623–628.
   Google Scholar
• ARVER S, DOBS AS, MEIKLE AW etal.: Long-term efficacyand safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol. (1997) 47:727–737.
   Google Scholar
• WILSON DE, MEIKLE AW, BOIKE SC, FAIRLESS AJ,ETHEREDGE RC, JORKASKY DK: Bioequivalence assess-ment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. J. Clin. Pharmacol. (1998) 38:54–59.
   Google Scholar
• HOGAN DJ, MAIBACH HI: Adverse dermatologicreactions to transdermal drug delivery systems." Am. Acad. Dermatol. (1990) 22:811–814.
   PubMed Web of Science ®Google Scholar
• MEIKLE AW, ANNAND D, HUNTER C et al.: Pre-treatmentwith a topical corticosteroid cream improves local tolerability and does not significantly alter the pharmacokinetics of the androderm testosterone transdermal system in hypogonadal men. Endocrine Society 79th Annual Meeting (1997):P01–322.
   Google Scholar
• WILSON DE, KAIDBEY K, BOIKE SC, JORKASKY DK: Useof topical corticosteroid cream in the pretreatment of skin reactions associated with Androderm testos-terone transdermal system. Endocrine Society 79th Annual Meeting (1997):P01–323.
   Google Scholar
• YU Z, GUPTA SK, HWANG SS, COOK DM, DUCKETT MJ,ATKINSON LE: Trandermal testosterone administra-tion in hypogonadal men: comparison ofpharmacoki-netics at different sites of application and at the first and fifth days of application. J. Clin. Pharmacol. (1997) 37:1129–1138.
   PubMed Web of Science ®Google Scholar
• YU Z, GUPTA SK, HWANG SS et al.: Testosteronepharmacokinetics after application of an investiga-tional transdermal system in hypogonadal men. J. Clin. Pharmacol. (1997) 37:1139–1145.
   PubMed Web of Science ®Google Scholar
• JORDAN JR. WP, ATHKINSON LE, LAI C: Comparison ofthe skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin. Ther. (1998) 20:80–87.
   PubMed Web of Science ®Google Scholar
• WANG C, BERMAN N, LONGSTRETH A et al.: Pharmacoki-netics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J. Clin. Endocrinol. Metab. (2000) 85:964–969.
   PubMed Web of Science ®Google Scholar
• •The relevance of this paper is documented by the original proposal and characterisation of gel delivery system in hypogonadal men.
   Google Scholar
• WANG C, SWERDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength and body composi-tion parameters in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85:2839–2853.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, WANG C, CUNNINGHAM G et al. Long-term pharmacokinetics of transdermal testos-terone gel in hypogonadal men. J Clin. Endocrinol. Metab. (2000) 85: 4500–4510.
   PubMed Web of Science ®Google Scholar
• STUENKEL A, DUDLEY RE, YEN SSC: Sublingual admini-stration of testosterone-hydroxypropy143-cyclode-xtrin inclusion complex simulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. Metab. (1991) 72:1054–1059.
   PubMed Web of Science ®Google Scholar
• SALEHIAN B, WANG C, ALEXANDER G eta]: Pharmacoki-netics, bioefficacy and safety of sublingual testos-terone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. J. Clin. Endocrinol. Metab. (1995) 80:3567–3575.
   PubMed Web of Science ®Google Scholar
• WANG C, EYRE DR, CLARK R et al.: Sublingual testos-terone replacement improves muscle mass and strength, decreases bone resorption and increases bone formation markers in hypogonadal men - a clinical research center study.J Clin. Endocrinol. Metab. (1996) 81:3654–3662.
   PubMed Web of Science ®Google Scholar
• •This study was performed in a relatively large population. The merit of this contribution relies on the accurate investi-gations about the clinical impact of the sublingual T delivery system.
   Google Scholar
• DOBS AS, HOOVER DR, CHEN M, ALLEN R: Pharmacoki- netic characteristics, efficacy and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin. Endocrinol. Metab. (1998) 83:33–39.
   PubMed Web of Science ®Google Scholar
• •The novelty of this preliminary study is due to the original proposal of the buccal testosterone delivery system as a safe and tolerable alternative to the traditional routes of T administration.
   Google Scholar
• BURRIS AS, EWING LL, SHERINS RJ: Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil. Steril (1988) 50:493–497.
   PubMed Web of Science ®Google Scholar
• BHASIN S, SWERDLOFF RS, STEINER B eta]: A biodegrad-able testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. (1992) 74:75–83.
   PubMed Web of Science ®Google Scholar
• •A complete study in which T microcapsule formulation is proposed as a good alternative for T delivery system.
   Google Scholar
• PEACOCK NR, SWERDLOFF RS, BERMAN N eta]: Pharma- cokinetics and pharmacodynamics of a parenteral testosterone microsphere formulation in the male rat. Demonstration of dose dependence and controlled release. J. Andra] (1993) 14:45–52.
   Google Scholar
• WEINBAUER GF, MARSHALL GR, NIESCHLAG E: New injectable testosterone ester maintains serum testos-terone of castrated monkeys in the normal range for four months. Acta Endocrinol. (1986) 113:128–132.
   PubMedGoogle Scholar
• BEHRE HM, NIESCHLAG E: Testosterone buciclate (20Aet-1) in hypogonodal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin. Endocrinol. Metab. (1992) 75:1204–1210.
   PubMed Web of Science ®Google Scholar
• PARTSCH CJ, WEINBAUER GF, FANG R, NIESCHLAG E: Injectable testosterone undecanoate has more favour-able pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur. J. Endocrinol. (1995) 1 3 2:514–519.
   Google Scholar
• BEHRE HM, ABSHAGEN K, OETTEL M, HOBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogona-dism: Phase I studies. Eur. J. Endocrinol. (1999) 140:414–419.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BOCHTER D, ECKARDSTEIN SV, ABSHAGEN K, SIMONI M, BEHRE HM: Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol. (1999) 51:757–763.
   PubMed Web of Science ®Google Scholar
• ZHANG G-Y, GU Y-Q, WANG X-H, CUI Y-G, BREMNER WJ:A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Androl. (1998) 19:761–768.
   PubMed Web of Science ®Google Scholar
• EDWARDS DA, HANES J, CAPONETTI G et al.: Largeporous particles for pulmonary drug delivery. Science (1997) 276:1868–1871.
   PubMed Web of Science ®Google Scholar
• •The paper describes in detail a new type of inhalation aerosol which provide high systemic bioavailability of T in rats.
   Google Scholar
• TENOVER JS: Effects of testosterone supplementationin the aging male. J. Clin. Endocrinol. Metab. (1992) 75:1092–1098.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, PERRY HM III, KAISER FE et al.: Effects oftestosterone replacement therapy in old hypogonadal males: A preliminary study. J Am. Geriatr. Soc. (1993) 41:149–152.
   PubMed Web of Science ®Google Scholar
• URBAN RJ, BODENBURG YH, GILKISON C et al.: Testos-terone administration to elderly men increases skeletal muscle strength and protein synthesis. Am. J Physiol. (1995) 269: E820–E826.
   PubMed Web of Science ®Google Scholar
• MARIN P, HOLMANG S, GUSTAFFSON C et al.:Androgen treatment of abdominally obese men. Obes. Res. (1993) 1:245–251.
   PubMedGoogle Scholar
• SIH R, MORLEY JE, KAISER FE, PERRY HM III, PATRICK P,ROSS C: Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. (1997) 82 :1661–1667.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, PEACHEY H, HANNOUSH P et al.: Effect oftestosterone treatment on bone mineral density in men over 65 years of age. J Clin. Endocrinol Metab. (1999) 84:1966–1972.
   PubMed Web of Science ®Google Scholar
• COLVARD DS, ERIKSEN EF, KEETING PE et al.: Identifica-tion of androgen receptors in normal human osteoblast-like cells. Proc. Natl. Acad. Sci. USA (1989) 86:854–857.
   PubMed Web of Science ®Google Scholar
• KASPERK CH, WERGEDAL JE, FARLEY JR, LINKHART TA,TURNER RT, BAYLINK DJ: Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology (1989) 1 2 4:1576–1578.
   Google Scholar
• BAGATELL CJ, BREMNER WJ: Androgen and progestageneffects on plasma lipids. Prog. Cardiovasc. Dis. (1995) 38:255–271.
   PubMed Web of Science ®Google Scholar
• ZGLICZYNSKI S, OSSOWSKI M, SLOWINSKA-SRZEDNICKA J et al.: Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis (1996) 121:35–43.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON 0, NORMING U, GUSTAFSSON S, ENEROTH P, ASTROM G, NYMAN CR: Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Br. J Ural. (1996) 77:433–440.
   PubMedGoogle Scholar
• CARTER HB, PEARSON JD, METTER EJ et al.: Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate (1995) 27:25–31.
   PubMed Web of Science ®Google Scholar
• GANN PH, HENNEKENS CH, LONGCOPE C, VERHOEK-OFTEDAHL W, GRODSTEIN F, STAMPFER MJ: A prospective study of plasma hormone levels, non hormonal factors and development of benign prostatic hyperplasia. Prostate (1995) 26:40–49.
   PubMed Web of Science ®Google Scholar
• HAJJAR RR, KAISER FE, MORLEY JE: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin. Endocrinol. Metab. (1997) 82:3793–3796.
   PubMed Web of Science ®Google Scholar
• SHAHIDI NT: Androgens and erythropoiesis. N. Engl. J. Med. (1973) 289:72–80.
   PubMed Web of Science ®Google Scholar
• MOORADIAN AD, MORLEY JE, KORENMAN SG. Biological actions of androgens. Endocr. Rev. (1987) 8:1–28.
   PubMed Web of Science ®Google Scholar
• BARRET-CONNOR E, VON MUHLEN DG, KRITZ-SILVERSTEIN D: Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo study. J. Clin. Endocrinol Metab. (1999) 84:573–577.
   PubMed Web of Science ®Google Scholar
• MORALES A, JOHNSTON B, HEATON JP, LUNDIE M: Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J. Ural (1997) 157:849–854.
   PubMed Web of Science ®Google Scholar
• TENOVER JL: Testosterone and the agingmale. J. Androl.(1997) 18:103–106.
   PubMed Web of Science ®Google Scholar